SecBot SecBot
SECBOTREPLAY Home › Report › CTSO

CTSO · Q3 rev $9.7M, OCF breakeven

Cytosorbents Corp · PRESS-RELEASE filed Nov 12, 2026 at 17:16 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 12, 2026 at 17:16 ET

CytoSorbents reported Q3 2026 revenue of $9.7M (+3% YoY), slightly below the $9.9M consensus, and a GAAP net loss of $0.58 per share, which was narrower than the $-0.90 consensus estimate. The company achieved operating cash flow breakeven (excluding restructuring payments), a key milestone, but revenue growth remains modest and the German market declined 20% YoY.

  • Revenue $9.7M, +3% YoY vs $9.5M (consensus $9.9M)
  • GAAP net loss $0.58 per share vs consensus $-0.90 (narrower loss)
  • Operating cash flow positive $43K (excluding $251K restructuring payments), achieving breakeven target
  • Gross margin improved to 75% from 70% a year ago

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access